ESPE Abstracts

56 patients under the care of the paediatric diabetes team at Wythenshawe Hospital were identified as current Omnipod® 5 insulin pump users for Type 1 Diabetes Mellitus management in April 2024. Time in range (TIR) i.e. the time spent with blood glucose in the normal range, total daily dose (TDD) of insulin, BMI Z-score along with total daily carbohydrate intake (CHO) and insulin boluses (TDB) during the first six months of pump therapy were compared against those of their previous insulin regime. Data was collected from the Manchester Foundation Trust’s HIVE EPR system, Dexcom Clarity and Glooko. Although the analysis was limited by incomplete patient records and a small sample size, a statistically significant increase in TIR was observed at 1, 3 and 6 months following transition, with 22 patients achieving a TIR above 60% after 6 months of use. After 6 months average TIR increased from 49.0% to 63.0% (P <0.0001). The most dramatic increase in TIR was observed in the cohort of patients under 5 years of age who previously used multiple daily injections (n = 4), from an average baseline TIR of 31.75% to 61.5% after 6 months of Omnipod® 5 use. The difference in the TDD of insulin was significant during the first three months, with an average rise of 31% in the first month and 24% in the third month, but this was no longer statistically significant by month six. This was correlated with a statistically significant increase in CHO and TDB after 1 month of use, but these increases became insignificant after 3 months for CHO and 6 months for TDB. Changes in BMI Z-Score were negligible and there was no association with TDD of insulin. Qualitative data was collected from 10 parents who participated in open telephone interviews, and all expressed their preference for Omnipod® 5 in contrast to their child's previous form of insulin therapy. Benefits were highlighted regarding improvements in quality of life for children and their families, however, issues were raised such as neurodiversity-related sensory issues, distress during pump changes and poor blood glucose control in the first few weeks following transition.